HOOKIPA Pharma(HOOK) - 2024 Q1 - Quarterly Results

● HOOKIPA is preparing to start a seamless pivotal Phase 2/3 trial of HB-200 in combination with pembrolizumab for the treatment of patients with Human Papillomavirus 16-positive (HPV16+) recurrent/metastatic PD-L1 CPS ≥ 20 oropharyngeal squamous cell carcinoma (OPSCC) in the first line setting. ● The Phase 2/3 trial design and protocol are based on alignment with the FDA following the Company's Type C meeting. ● EMA granted PRIME designation to the investigational product HB-200 in combination with pembrol ...